Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydroxytyrosol + vitamin E is a combination of two antioxidant compounds—hydroxytyrosol, a phenolic compound primarily found in olive oil, and vitamin E (tocopherols/tocotrienols), a fat-soluble antioxidant. This combination has been studied for its potential therapeutic effects in non-alcoholic fatty liver disease (NAFLD), particularly for reducing liver fibrosis. Mechanistically, the combination acts by reducing oxidative stress and inflammation; it inhibits pro-fibrogenic gene expression in hepatic stellate cells activated by TGF-β signaling, reduces NOX2-mediated oxidative stress via interference with SMAD2/3 nuclear translocation/activation, and decreases circulating markers of fibrosis such as PIIINP. In both animal models and pediatric patients with NAFLD, supplementation with hydroxytyrosol plus vitamin E improved histological features of fibrosis as well as systemic markers of oxidative stress[1][2][6]. The combination is not an approved pharmaceutical drug but is being explored as a dietary supplement or nutraceutical intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroxytyrosol + vitamin E.